A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
The in vivo proof of concept of a novel double-coating system, based on enteric polymers, which accelerated drug release in the ileo-colonic region, was investigated in humans. Prednisolone tablets were coated with a double-coating formulation by applying an inner layer composed of EUDRAGIT S neutralised to pH 8.0 and a buffer salt (10% KH₂PO₄), which was overcoated with layer of standard EUDRAGIT S organic solution. For comparison, a single coating system was produced by applying the same amount of EUDRAGIT S organic solution on the tablet cores. Dissolution tests on the tablets were carried out using USP II apparatus in 0.1N HCl for 2 h and subsequently in pH 7.4 Krebs bicarbonate buffer. For comparison, tablets were also tested under the USP method established for modified release mesalamine formulations. Ten fasted volunteers received the double-coated and single-coated tablets in a two-way crossover study. The formulations were radiolabelled and followed by gamma scintigraphy; the disintegration times and positions were recorded. There was no drug release from the single-coated or double-coated tablets in 0.1N HCl for 2h. The single-coated tablets showed slow release in subsequent Krebs bicarbonate buffer with a lag time of 120 min, while in contrast drug release from the double-coated tablets was initiated at 60 min. In contrast, using the USP dissolution method, normally employed for modified release mesalamine products, no discrimination was attained. The in vivo disintegration of the single-coated EUDRAGIT S tablets in the large intestine was erratic. Furthermore, in 2 volunteers, the single-coated tablet was voided intact. Double-coated tablets disintegrated in a more consistent way, mainly in the ileo-caecal junction or terminal ileum. The accelerated in vivo disintegration of the double-coating EUDRAGIT S system can overcome the limitations of conventional enteric coatings targeting the colon and avoid the pass-through of intact tablets. Moreover, Krebs bicarbonate buffer has the ability to discriminate between formulations designed to target the ileo-colonic region.
Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK.
F J O
FJ
Varum
G B
GB
Hatton
A C
AC
Freire
A W
AW
Basit
D000328:Adult; D001639:Bicarbonates / Q000737:chemistry; D002021:Buffers; D002626:Chemistry, Pharmaceutical / Q000379:methods; D018592:Cross-Over Studies; D016503:Drug Delivery Systems; D015195:Drug Design; D005772:Gastrointestinal Transit; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007082:Ileum / Q000378:metabolism*; D008297:Male; D011109:Polymethacrylic Acids / Q000737:chemistry; D011239:Prednisolone / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging / Q000379:methods*; D013607:Tablets; D013608:Tablets, Enteric-Coated / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D013997:Time Factors
D001639:Bicarbonates; D002021:Buffers; D011109:Polymethacrylic Acids; D013607:Tablets; D013608:Tablets, Enteric-Coated; C038300:methylmethacrylate-methacrylic acid copolymer; D011239:Prednisolone